| 前收盘价格 | 3.84 |
| 收盘价格 | 3.80 |
| 成交量 | 1,251,591 |
| 平均成交量 (3个月) | 675,423 |
| 市值 | 130,621,608 |
| 价格/销量 (P/S) | 0.270 |
| 股市价格/股市净资产 (P/B) | 0.940 |
| 52周波幅 | |
| 利润日期 | 5 Feb 2025 - 10 Feb 2025 |
| 营业毛利率 | -19.80% |
| 营业利益率 (TTM) | -17.29% |
| 稀释每股收益 (EPS TTM) | -4.19 |
| 季度收入增长率 (YOY) | -32.80% |
| 总债务/股东权益 (D/E MRQ) | 236.01% |
| 流动比率 (MRQ) | 0.310 |
| 营业现金流 (OCF TTM) | 14.33 M |
| 杠杆自由现金流 (LFCF TTM) | 26.63 M |
| 资产报酬率 (ROA TTM) | -2.91% |
| 股东权益报酬率 (ROE TTM) | -43.15% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 混合的 | 混合的 | |
| 股票 | Inotiv, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.00 |
|
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 13.48% |
| 机构持股比例 | 13.92% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Kpp Advisory Services Llc | 30 Sep 2024 | 237,718 |
| Fi3 Financial Advisors, Llc | 30 Sep 2024 | 80,710 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合